A Phase 2 proof-of-concept trial of BRB-002 in patients with established atherosclerosis
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs BRB-002 (Primary)
- Indications Atherosclerosis
- Focus Proof of concept; Therapeutic Use
- 13 Jan 2025 New trial record
- 08 Jan 2025 According to Bitterroot Bio media release, company expected to initiate this trial in the first half of 2025.